Ok so let me get this straight: Amazon just body bagged Temu and Shein with its Amazon Haul- and now, they are coming for Hims and Hers’ hair meds? Talk about ruthless.

(Source: Giphy) 

In short, Amazon is launching its shiny new telehealth service, One Medical Pay-per-Visit, and undercutting Hims’ prices like they’re slashing the cost of phone chargers on Prime Day. Naturally, this news sent Hims shares to the sh*tter, plummeting nearly -15% (down -20.51% this week) after Amazon said, “Deal with it.”

(Source: Wall Street Journal) 

Now, what’s interesting here is that this news wasn’t necessarily way out in left field - especially since Amazon’s been circling the healthcare sector like and this latest move feels like the moment they finally decided to take a big ol’ bite. First came Amazon Clinic in 2022, which was a cutesy and demure…  but now, with One Medical, it’s like they’ve upgraded to the all-you-can-eat buffet of medical services: Amazon-affiliated doctors, bargain-basement prices, and the kind of convenience that makes you wonder why Hims is even trying anymore.

What’s more is that Amazon is stepping right into Him’s territory with hair loss treatments starting at $16 a month, anti-aging skincare at just $10 a month, and erectile dysfunction meds for $19 a month. Meanwhile, Hims charges more for the same stuff, but they throw in the cost of provider visits as part of the subscription. Ok, cool - but Amazon’s à la carte model is starting to look like the better deal for people who don’t need a doctor holding their hand every time they need a pick me up for good ole Richard.

(Source: Giphy) 

Naturally, this has Citi analysts out here sounding the alarm, calling this a major threat to Hims. And, well, duh. Amazon’s new service covers over 30 conditions—think pink eye, flu, sinus infections—at prices that make you feel like you’re getting away with something. Plus, Prime members can chat with a doctor for $29 or hop on a video call for $49. The best part? Prescriptions get filled through Amazon Pharmacy, because of course they do.

(Source: Yahoo Finance) 

Now with that said, despite the stock getting body-slammed, Hims’ loyal retail investors seem to be unphased. In fact, according to our good friends at StockTwits, Hims was trending Thursday yesterday, as one bullish user straight-up dismissed Amazon’s threat, pointing out that they’ve been in the healthcare game for years without managing to take down Hims. Remember Haven Healthcare? (Yeah, neither does anyone else. RIP.)

But here’s the thing: Amazon doesn’t need to win overnight. They just need to keep the pressure on. And if there’s one thing Amazon excels at, it’s grinding down the competition with lower prices and faster shipping until everyone else taps out.

(Source: Giphy) 

Plus, let’s not forget that while hair loss and ED are Hims’ bread and butter, they’ve recently struck gold with GLP-1 weight-loss drugs. For instance, Novo Nordisk’s Wegovy has been flying off the shelves—when it’s actually available—and Hims has been riding that wave for all it’s worth. 

Hell, they even launched a tracker to help patients find these drugs during the constant shortages, which is either a brilliant move or a sign of just how bad the supply chain has gotten. But for now, Amazon isn’t offering compounded GLP-1 drugs, so Hims still has a bit of breathing room in this lucrative space.

(Source: Yahoo Finance) 

On the other hand, the market’s already crowded with players like Hims, Ro, and GoodRx, all trying to sell cheap generics with flashy marketing. But now that Amazon’s come in swinging, looking to undercut everyone with prices so low, you can practically hear Hims and Ro sweating. 

In the end though, sure, Him & Hers is getting knocked around like Jake Paul is about to be tonight (he’s fighting Mike Tyson, so yeah), but they’re not out of the game. Amazon’s pricing might be scary, but Hims still has its secret weapon: personalized treatments and a fiercely loyal retail base that isn’t jumping ship just yet. 

(Source: StockTwits) 

Plus, that girthy GLP-1 money is giving them plenty of cushion while Amazon figures out how to steamroll the rest of the telehealth space. So, going forward, who’s going to win? Well, Amazon might have the firepower, but Hims isn’t folding just because Daddy Warbucks (Andy Jassy) has shown up unannounced. 

In the meantime, let this battle for the future of your hairline and your healthcare continue… because, now with Amazon in the mix - it’s anyone’s game. So with that said, place your bets accordingly friends and as always - stay safe and stay frosty! Until next time…

P.S. Life comes at you fast friends, and while your gavorite online stock guru is out here struggling to make heads or tails on the markets short-term direction - our team and our premium members at Stocks.News are absolutely CRUSHING it. How so? Well it all comes down to back-to-back-to-back-to-back-to-back massive wins over the last few weeks. Don’t believe me? Click here to see for yourself once we drop our next alert. 

Stocks.News does not hold positions in Amazon as mentioned in the article.